Quince Therapeutics Changes Name to IRulya Therapeutics and Appoints New Leadership

Quince Therapeutics, Inc. has filed an -K with the Securities and Exchange Commission announcing a rebranding and significant changes to its executive leadership team. The company will change its name to IRulya Therapeutics Inc. effective at 4:01 p.m. Eastern Time on October 9, 2026. Concurrently, the company’s common stock will begin trading on the Nasdaq Capital Market under the ticker symbol “IRLA” effective October 12, 2026.

The leadership transition follows the resignation of Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., and Chief Operating Officer Brendan Hannah, effective October 8, 2026. The Board of Directors has appointed Brigette Roberts, M.D., as the new Chief Executive Officer. Dr. Roberts has served as the company’s Chief Corporate Affairs Officer and member of the Board since May 2026. Prior to this, she was the Chief Executive Officer of Orphai Therapeutics, Inc. from May 2021 until May 2026. Dr. Roberts will receive an annual base salary of $600,000 and a target annual bonus of 50% of her base salary.

John Militello, CPA, has been appointed as Chief Financial Officer. Mr. Militello previously served as Head of Finance at Quince and held senior financial roles at Rocket Pharmaceuticals, Inc. He will receive an annual base salary of $440,000 and a target annual bonus of 45% of his base salary. Additionally, he is entitled to a restricted stock unit award of 80,000 shares of common stock, which will vest over four years.

Keith R. Fandrick, Ph.D., has been appointed as Chief Operating Officer. Dr. Fandrick previously served as Head of Technical Operations at Quince and Chief Operating Officer of Orphai Therapeutics. He will receive an annual base salary of $450,000 and a target annual bonus of 45% of his base salary.

In addition to the executive appointments, the company announced the addition of five new members to its Board of Directors: Catherine Bonuccelli, M.D.; Leone Patterson; James Valentine, J.D., M.H.S.; and Drayton Wise. The company reported a cash balance of $116 million as of June 30, 2026, which is expected to fund operations through the end of 2028.